


CPT-157633

Cat. No.:	HY-111469
CAS No.:	888213-72-7
Molecular Formula:	C ₁₂ H ₁₆ BrF ₂ N ₂ O ₆ PS
Molecular Weight:	465.2
Target:	Phosphatase
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (429.92 mM; Need ultrasonic)						
	H ₂ O : 100 mg/mL (214.96 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.1496 mL	10.7481 mL	21.4961 mL
				5 mM	0.4299 mL	2.1496 mL	4.2992 mL
10 mM				0.2150 mL	1.0748 mL	2.1496 mL	
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (10.75 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (10.75 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (10.75 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	CPT-157633, a difluoro-phosphonomethyl phenylalanine derivative, and is a PTP1B inhibitor. CPT-157633 prevents binge drinking-induced glucose intolerance ^[1] .
In Vivo	CPT-157633 (0.2 μg/day; intracerebroventricular infusion) alleviates the hypothalamic inflammation and glucose intolerance induced by binge drinking in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lindtner C, et, al. Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action. Sci Transl Med. 2013 Jan 30;5(170):170ra14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA